REVANCE THE
NASDAQ: RVNC (Revance Therapeutics, Inc.)
Kemas kini terakhir: 12 jam lalu3.65
-0.02 (-0.54%)
| Penutupan Terdahulu | 3.67 |
| Buka | 3.65 |
| Jumlah Dagangan | 3,180,269 |
| Purata Dagangan (3B) | 3,114,090 |
| Modal Pasaran | 381,023,520 |
| Harga / Jualan (P/S) | 1.37 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -71.78% |
| Margin Operasi (TTM) | -53.87% |
| EPS Cair (TTM) | -3.34 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.70% |
| Nisbah Semasa (MRQ) | 4.12 |
| Aliran Tunai Operasi (OCF TTM) | -190.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -167.85 M |
| Pulangan Atas Aset (ROA TTM) | -24.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Revance Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -0.21 |
|
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 8.56% |
| % Dimiliki oleh Institusi | 87.64% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |